Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly EBT Margin came in at 320.1% in Q2 2026, up 73945.0% YoY from N/an in Q2 2025, and up 55.06% on a QoQ basis from 712.22% in Q1 2026.
Powered by 
Analysis
Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 14 years of EBT Margin data on file, last reported at 320.1% in Q2 2026.
- Quarterly EBT Margin rose 73945.0% year-over-year to 320.1% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 511.98% (down 210759.0% YoY) and the FY2025 annual result came in at 765.89%, down 273304.0% from the prior year.
- EBT Margin grew to 320.1% in Q2 2026, from 712.22% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 11167.28% in Q3 2024 to a low of 12527.28% in Q1 2022.
- A 5-year average of 1203.29% and a median of 1255.84% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 1240156 bps — and 2025, when it slumped 1197033 bps.
- Tracing AGIO's EBT Margin over 5 years: stood at 2253.11% in 2022, then jumped by 40 bps to 1350.7% in 2023, then rose by 27 bps to 982.28% in 2024, then jumped by 44 bps to 546.18% in 2025, then soared by 41 bps to 320.1% in 2026.
- The last three EBT Margin figures came in at 320.1% (Q2 2026), 712.22% (Q1 2026), and 546.18% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Agios Pharmaceuticals | 1.97 Bn | 1.97 Bn | 41.75 Mn | -225.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -225.33% |
| Mar 31, 2026 | -478.31% |
| Dec 31, 2025 | -546.18% |
| Sep 30, 2025 | -803.05% |
| Jun 30, 2025 | -903.60% |
| Mar 31, 2025 | -1,037.61% |
| Dec 31, 2024 | -982.28% |
| Sep 30, 2024 | 11,167.28% |
| Jun 30, 2024 | -1,134.03% |
| Mar 31, 2024 | -1,015.79% |
| Dec 31, 2023 | -1,350.70% |
| Sep 30, 2023 | -1,234.27% |
| Jun 30, 2023 | -1,273.03% |
| Mar 31, 2023 | -1,471.24% |
| Dec 31, 2022 | -2,150.44% |
| Sep 30, 2022 | -2,482.14% |
| Jun 30, 2022 | -1,717.07% |
| Mar 31, 2022 | -12,073.44% |
| Dec 31, 2020 | -191.94% |
| Sep 30, 2020 | -228.13% |